Opus Genetics (IRD) stock price, chart and financials
Price chart
Financials
- Revenue (quarter)
- $755,000.00
- Gross margin
- 100.00%
- Net income (quarter)
- −$8.1M
- Net margin
- −1091.82%
- Return on equity
- −4796.52%
- Book value per share
- −$0.16
- Debt to assets
- 113.97%
Company profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Frequently asked questions
Is Opus Genetics (IRD) profitable?
No. Opus Genetics reported a net loss of $107.6M over the trailing twelve months.
How much revenue does Opus Genetics (IRD) make?
Opus Genetics generated $9.9M in revenue over the trailing twelve months, down 73.80% year over year.
How do I buy stock in Opus Genetics (IRD)?
IRD trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.